SCHEMBL9958013

SCHEMBL9958013

[c]1ccc(-c2ccncc2)c(-c2ccncc2)c1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 5/20 0.43
LMNA P02545 1/20 0.43
NOTUM Q6P988 1/20 0.37
GSK3B P49841 3/20 0.33
SMN1; SMN2 Q16637 2/20 0.33
RPS6KA3 P51812 2/20 0.33
NFATC1 O95644 2/20 0.33
DYRK1A Q13627 2/20 0.33
TP53 P04637 1/20 0.33
PKM P14618 1/20 0.33
DDAH1 O94760 1/20 0.33
NOS1 P29475 1/20 0.33
IMPDH2 P12268 1/20 0.33
MAPK1 P28482 1/20 0.33
HSD17B10 Q99714 1/20 0.33
ALDH1A1 P00352 1/20 0.33
TSHR P16473 1/20 0.33
HTT P42858 1/20 0.33
NPC1 O15118 1/20 0.33
RAB9A P51151 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9958265 0.92 NOTUM (0.52) MAPTLMNANOTUMGSK3BSMN1; SMN2
SCHEMBL9957984 0.92 NOTUM (0.52) MAPTLMNANOTUMGSK3BSMN1; SMN2
SCHEMBL27581883 0.81 LMNA (0.39) MAPTLMNANOTUMGSK3BSMN1; SMN2
SCHEMBL27343606 0.81 MAPT (0.39) MAPTLMNANOTUMSMN1; SMN2IMPDH2
SCHEMBL27934527 0.81 LMNA (0.39) MAPTLMNANOTUMPKMNPC1
SCHEMBL28038295 0.81 MAPT (0.39) MAPTLMNANOTUMGSK3BSMN1; SMN2
SCHEMBL16720179 0.81 QDPR (0.39) MAPTLMNANOTUMSMN1; SMN2RPS6KA3
SCHEMBL9957921 0.80 NPC1 (0.42) MAPTLMNANOTUMSMN1; SMN2TP53
SCHEMBL9957629 0.80 NPC1 (0.42) MAPTLMNANOTUMSMN1; SMN2TP53
SCHEMBL9958487 0.77 NOTUM (0.48) MAPTLMNANOTUMGSK3BSMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9624193-B2 Cyclic azine derivatives, processes for producing these, and organic electroluminescent element containing these as component TOSOH CORPORATION (JP) 2017-04-18 US disclosed
CN-102574813-B Cyclic azine derivatives, process for producing the same, and organic electroluminescent element containing the same as constituent TOSOH CORP. (JP) 2016-03-30 CN disclosed
US-20150329544-A1 CYCLIC AZINE DERIVATIVES, PROCESSES FOR PRODUCING THESE, AND ORGANIC ELECTROLUMINESCENT ELEMENT CONTAINING THESE AS COMPONENT TOSOH CORPORATION (JP) 2015-11-19 US disclosed
US-9120773-B2 Cyclic azine derivatives, processes for producing these, and organic electroluminescent element containing these as component TOSOH CORPORATION (JP) 2015-09-01 US disclosed
EP-2818462-A1 Cyclic azine derivatives, processes for producing these, and organic electrolumiscent element containing these as component TOSOH CORPORATION (JP) 2014-12-31 EP disclosed
US-20120214993-A1 CYCLIC AZINE DERIVATIVES, PROCESSES FOR PRODUCING THESE, AND ORGANIC ELECTROLUMINESCENT ELEMENT CONTAINING THESE AS COMPONENT SAGAMI CHEMICAL RESEARCH INSTITUTE, (JP) 2012-08-23 US disclosed
EP-2468731-A1 CYCLIC AZINE DERIVATIVES, PROCESSES FOR PRODUCING THESE, AND ORGANIC ELECTROLUMINESCENT ELEMENT CONTAINING THESE AS COMPONENT Tosoh Corporation (JP) 2012-06-27 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150329544-A1 CYCLIC AZINE DERIVATIVES, PROCESSES FOR PRODUCING THESE, AND ORGANIC ELECTROLUMINESCENT ELEMENT CONTAINING THESE AS COMPONENT CPNE4, EPB41, AZI2 MAPT 4430/4885LMNA 2703/4885NOTUM 2918/4885
US-20120214993-A1 CYCLIC AZINE DERIVATIVES, PROCESSES FOR PRODUCING THESE, AND ORGANIC ELECTROLUMINESCENT ELEMENT CONTAINING THESE AS COMPONENT CPNE4, EPB41, AZI2 MAPT 4430/4885LMNA 2703/4885NOTUM 2918/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.